Participants in the study will receive injections of either the vaccine or a placebo over a period of up to 12 months. The study will monitor the participants’ symptoms and any medication they use during the grass and olive tree pollen season, which typically occurs in April, May, and June. The study will also look at the number of days participants are free from symptoms and medication, any worsening of asthma symptoms, and overall quality of life related to rhinitis. Additionally, the study will assess the safety of the vaccine by tracking any side effects or reactions at the injection site.

The trial aims to provide valuable information on whether the vaccine can help reduce symptoms and improve the quality of life for people with allergies to grasses and olive trees. By comparing the vaccine to a placebo, researchers hope to determine its effectiveness in managing these allergic conditions. The study will also gather data on various health measures, including levels of specific antibodies in the blood, to better understand the vaccine’s impact on the immune system.

In the study, participants receive repeated injections over about one year. During this time, symptoms, asthma problems if present, and any unwanted effects are tracked in a diary and during study visits. The study looks at whether the treatment can help control allergy symptoms and improve day-to-day comfort in people allergic to dust mites and Blomia tropicalis.

The study is designed for people with allergy caused by Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Blomia tropicalis, which are types of house dust mites and a related allergen source. The purpose of the study is to evaluate the efficacy and safety of this allergy treatment in rhinitis/rhinoconjunctivitis with or without controlled mild to moderate asthma.

People in the study are assigned by chance to receive either the active injection or placebo, and neither the participants nor the study team know which one is given. The treatment is given under the skin over a period of time. During the study, allergy and asthma symptoms, use of allergy or asthma medicines, and possible side effects are followed over about one year of treatment.

The study includes people with moderate to severe allergy symptoms, with or without controlled mild asthma. It is designed to learn whether this form of immunotherapy, a treatment that helps the body become less sensitive to an allergen, can improve day-to-day symptoms and safety in people allergic to these dust-related allergens.

The research aims to determine how well the immunotherapy works compared to a placebo during the periods when pollen levels are highest. Participants will receive a series of injections. During the course of the study, information regarding symptoms such as sneezing, a runny nose, itchy eyes, or breathing difficulties will be recorded. The study also considers the use of other medications, such as antihistamines or intranasal corticoids, which are sprays used to reduce inflammation in the nose.

The research is conducted in different stages. Initially, a phase involves a double-blind process, where neither the participants nor the researchers know who is receiving the active medication or the placebo. During this stage, participants receive regular injections, and their symptoms and use of medications like antihistamines or intranasal corticoids are monitored. This is followed by an open-label phase, where the treatment details are known to everyone involved. This part of the study looks at how the body responds to different amounts of pollen through a conjunctival provocation test, which is a method used to see how the eyes react when exposed to allergens.

The purpose of this study is to see how well bilastine works in children between 6 and 11 years old who have allergic rhinoconjunctivitis, and to check if it is safe and if it improves their quality of life. Children in the study will take 10 milligrams of bilastine every day for 14 days. During the study, the children or their parents will record allergy symptoms each day using an electronic diary, noting how severe the symptoms like sneezing, runny nose, itching, and watery eyes have been over the previous day.

The study will measure changes in these five main symptoms from the beginning of the treatment to the end of the 14-day period to determine if the medicine is effective. Children participating in the study must have had allergic rhinoconjunctivitis for at least one year and must have allergy symptoms at the time they join the study. They also need to have had a positive allergy test in the past year and must have responded well to allergy medicines before. The study will also include some basic health checks like blood tests and heart rhythm tests to make sure the children are healthy enough to participate.

The purpose of this study is to determine how well each dose of the treatment works and how safe it is by measuring symptoms and the need for rescue medication. The study will also examine which dose provides the best balance between effectiveness and safety. During the study, participants will use an electronic diary to record their symptoms and any medication they take. The treatment is given as a spray under the tongue and will be administered over a period of time. The study will measure various aspects of the participants’ condition, including how severe their symptoms are, how often they need to use rescue medication, and how their quality of life is affected by their allergies.

Before and after the treatment period, participants will undergo a nasal provocation test, which involves exposing the inside of the nose to increasing amounts of house dust mite extract to see how the body reacts. This test helps determine whether the treatment has made the immune system less sensitive to the allergen. The study will track the number of days when participants feel well, when symptoms are severe, and when they are completely free of symptoms. Quality of life will be measured using questionnaires, and participants will rate their overall discomfort using a scale. Safety will be monitored throughout the study by recording any unwanted reactions to the treatment.

The purpose of the study is to find out if this type of allergy treatment is effective and safe for teenagers and adults who suffer from moderate to severe allergic reactions to grass pollen. The treatment aims to help reduce allergy symptoms and improve quality of life during the pollen season. The study will measure how well the treatment works by looking at symptom scores, which track how severe the allergy symptoms are, and medication scores, which record how much allergy medicine people need to use. Quality of life questionnaires will also be used to understand how the allergy affects daily activities and well-being.

During the study, participants will receive either the allergen treatment or the salt water solution over a period of several months. The allergen extract used in the treatment contains substances that trigger allergic reactions, and by giving small controlled amounts, the body may learn to tolerate these substances better over time. The study will track symptoms throughout the grass pollen season and measure any changes in how participants feel and function. For those who also have asthma related to grass pollen, additional questionnaires will assess asthma symptoms and control. The entire study will last for about one year, with treatment given over several months and follow-up continuing through the pollen season.

The study will involve children and teenagers between 4 and 18 years old who have moderate to severe symptoms and have experienced flare-ups of the condition in the past year. Participants will receive one of the two eye drop treatments for about six months. During this time, doctors will check how the eyes are responding to treatment by looking at changes in corneal damage, symptoms like itching and tearing, and overall eye health. The study will measure these changes at different time points, starting from the beginning of treatment through the end of the study period. Doctors will use special scales and measurements to track improvements in eye surface damage and will ask participants about their symptoms and quality of life.

Throughout the study, safety will be monitored by checking for any unwanted effects from the eye drops, measuring blood pressure and other vital signs, and doing blood tests to check kidney and liver function. For participants receiving T1695, blood samples will be taken to measure the amount of tacrolimus in the bloodstream. The study will also track whether participants need additional rescue medications and whether the condition comes back after treatment is stopped. The entire study will last several months and will help determine which treatment is more effective and safer for managing this eye condition in young people.

The purpose of this study is to determine which dose level of CLU-RX-PHL works best and is best tolerated by patients. The study will compare three different strengths of CLU-RX-PHL (high, medium, and low dose) against a placebo. The treatment will be given over a period of 50 weeks.

During the study, participants will receive injections of either CLU-RX-PHL or placebo. The effectiveness of the treatment will be measured during the grass pollen season by tracking allergy symptoms and the use of additional allergy medications. Participants will need to keep track of their symptoms using an electronic diary. The study team will monitor participants’ health throughout the treatment period to ensure safety.

The purpose of the study is to determine how well different doses of SLI-RX-PHL work and how safe they are for treating grass pollen allergies. The treatment will be tested in three different strengths (low, medium, and high dose), and some participants will receive a placebo. The medication or placebo will be given as a spray that is applied under the tongue.

The study will take place during grass pollen season, when allergy symptoms are typically most severe. Participants will need to keep a daily record of their allergy symptoms and any additional medications they need to take for symptom relief. The treatment period will last up to 50 weeks, during which the effectiveness of the medication will be measured by tracking how well it reduces allergy symptoms and the need for additional relief medications.

The purpose of this study is to find the most effective and safest dose of SLI-RX-BET for treating birch pollen allergies. The medication will be tested in three different strengths (low, medium, and high dose), and some participants will receive a placebo. The treatment involves daily use of the spray for approximately 10 months.

During the study, participants will need to track their allergy symptoms and use of additional medications during the birch pollen season. The treatment is specifically designed for people who have experienced moderate to severe allergic symptoms from birch pollen for at least two years. The medication aims to help reduce allergy symptoms and decrease the need for other allergy medications.

The purpose of the study is to evaluate how effective and safe this vaccine is for people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate controlled asthma. Participants will receive either the vaccine or a placebo, which looks like the vaccine but does not contain the active ingredients. The study will last for about a year, during which participants will receive regular injections and will be asked to keep track of their symptoms and any medications they use in a diary.

Throughout the study, participants’ symptoms and medication use will be closely monitored to assess the vaccine’s effectiveness. The study will also look at various health measures, including the quality of life related to asthma and rhinitis, and any side effects that may occur. The goal is to determine if the vaccine can help reduce the symptoms of allergic rhinitis and rhinoconjunctivitis and improve the overall quality of life for those affected by these conditions.

The purpose of the study is to assess how effective and safe this vaccine is compared to a placebo, which looks like the real treatment but does not contain any active ingredients. Participants in the study will receive either the vaccine or the placebo over a period of time. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. It will also look at the safety of the treatment by checking for any side effects.

Participants will be asked to keep track of their symptoms and any medications they take in a diary. The study will include people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The trial aims to provide valuable information on whether this new vaccine can offer relief to those affected by house dust mite allergies.

The study will compare three different doses of CLU-RX-BET (high, medium, and low) against a placebo. The treatment will be given through subcutaneous injections, which means the medication is injected beneath the skin. The study medication contains modified birch pollen extract that has been treated with a substance called glutaraldehyde to make it safer for treatment.

During the study, participants will receive multiple injections over a period of 50 weeks. They will need to track their allergy symptoms and use of additional medications during the birch pollen season. The effectiveness of the treatment will be measured by monitoring how well it reduces allergy symptoms and the need for other allergy medications compared to the placebo treatment.

The purpose of the study is to evaluate the safety and effectiveness of this immunotherapy treatment. Participants will receive injections of the allergens at different doses, and some will receive a placebo. The study will last for a period during which participants will receive 12 maintenance doses. Throughout the study, participants will be monitored to see how their symptoms change and to ensure the treatment is safe. The study aims to find the optimal dose that provides the best balance of benefits and risks.

Participants will be assessed on various factors, including changes in their symptoms, medication use, and quality of life. The study will also look at how well the treatment helps control asthma symptoms for those who have it. Regular check-ups will be conducted to track progress and any side effects. The ultimate goal is to determine if this immunotherapy can effectively reduce symptoms and improve the quality of life for people with these allergic conditions.

The purpose of the study is to find the most effective and best-tolerated dose of CLU-RX-DPT for people with moderate-to-severe allergic rhinitis due to house dust mites. Participants in the study will receive either one of the doses of CLU-RX-DPT or a placebo, which looks and feels like the treatment but does not contain the active allergen. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications over a period of time.

Throughout the study, participants will be asked to keep track of their symptoms and any allergy medications they use. This information will help researchers understand how the treatment affects daily life and overall comfort. The study will also look at how the treatment impacts the quality of life for those with allergic rhinitis. The goal is to determine which dose of CLU-RX-DPT provides the best balance of benefits and side effects for managing symptoms of house dust mite allergies.

Participants in the study will be randomly assigned to receive either the Cup a 1 treatment or a placebo, which is a substance with no active therapeutic effect. Neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, ensuring that the results are unbiased. The treatment will be administered as a suspension for injection under the skin, known as subcutaneous use. The study will take place over two pollen seasons, during which participants will complete questionnaires to report the frequency and severity of their symptoms.

The primary goal of the study is to assess how well the Cup a 1 treatment works in reducing allergy symptoms compared to the placebo. This will be measured by a combination of symptom scores and medication use. Secondary goals include evaluating the number of symptom-free and medication-free days, as well as any additional doctor visits or emergencies related to the allergies. The study will also monitor any side effects and changes in specific immune markers in the participants. The trial is expected to continue until March 2025.

The purpose of the study is to evaluate how effective and safe the Sublingual MM09 treatment is compared to a placebo, which looks like the treatment but does not contain the active ingredients. Participants in the study will use the spray daily for 12 months. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. Participants will be asked to keep a diary of their symptoms and any medications they take during the study.

This trial is designed to be a double-blind study, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will include people aged 12 to 65 who have been diagnosed with moderate to severe rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, due to house dust mite allergies. The goal is to see if the Sublingual MM09 can help improve their quality of life by reducing allergy symptoms and the need for other treatments.

The purpose of the study is to evaluate how well the vaccine works in reducing symptoms and the need for medication during the pollen seasons of grasses and cupressaceae, which are types of plants that can cause allergies. Participants will receive the vaccine or placebo over a period of 12 months. Throughout the study, participants will be monitored for any changes in their symptoms, the number of days they are symptom-free, and any asthma flare-ups. The study will also assess the overall safety of the vaccine by tracking any side effects or reactions at the injection site.

Participants will be asked to record their symptoms and medication use using a smartphone app. The study will also measure certain immune system markers, such as total IgE and specific IgG4, which are types of antibodies related to allergies. Additionally, the study will evaluate the participants’ quality of life and asthma control using questionnaires. The trial aims to provide valuable information on whether this new vaccine can help people with grass and cupressaceae allergies manage their symptoms more effectively.

The purpose of the study is to evaluate how well this vaccine works in reducing allergy symptoms and the need for medication in people who are allergic to these dust mites. Participants in the study will receive either the Clustoid MM09 vaccine or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for up to 12 months, during which participants will receive regular injections and will be monitored for any changes in their allergy symptoms and overall health.

Throughout the study, participants will be asked to keep track of their symptoms and any medications they take using a smartphone app. The study aims to provide valuable information on the potential benefits of the Clustoid MM09 vaccine for people with dust mite allergies, potentially leading to improved treatment options for those affected by these common allergens.

The purpose of the study is to assess how well the vaccine works in reducing allergy symptoms in adolescents and adults who suffer from these conditions. Participants will receive the vaccine or placebo through injections over a period of time. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual vaccine or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored to see how their symptoms change during the peak birch pollen season. The main goal is to determine if the vaccine can effectively reduce the symptoms and the need for other allergy medications. This research could lead to a new way to manage birch pollen allergies and improve the quality of life for those affected by these seasonal conditions.

The purpose of the study is to evaluate the safety and effectiveness of STALORAL® Birch 300 IR in children and adolescents aged 5 to 17 years. Participants in the study will be randomly assigned to receive either the STALORAL® Birch 300 IR treatment or a placebo, which is a substance with no active medication. Neither the participants nor the doctors will know which treatment is being given to ensure unbiased results. The study will last for a period of up to 13 months, during which participants will regularly use the treatment and report their symptoms and any changes they experience.

Throughout the study, participants will be monitored to assess how well the treatment works in reducing symptoms of allergic rhinoconjunctivitis and the need for additional medication. The trial aims to provide valuable information on whether STALORAL® Birch 300 IR can be a safe and effective option for managing symptoms in young people with birch pollen allergies, potentially improving their quality of life during the pollen season.

The purpose of the study is to evaluate how effective and safe PQ Grass is for children and teenagers with these allergies. Participants in the study will receive either the PQ Grass treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will be conducted over several years to see if the benefits of the treatment last even after stopping the injections. During the study, participants will have regular check-ups to monitor their health and any changes in their allergy symptoms.

Throughout the trial, participants will be asked to visit the study site for assessments and to receive their injections. The study aims to provide valuable information on whether PQ Grass can offer long-term relief from grass pollen allergies in young people. This research could potentially lead to better treatment options for those affected by seasonal allergies.

During the study, participants will be monitored to see how their symptoms change over time. The study will compare the symptoms and medication use of those receiving the active treatment with those receiving the placebo. This will help determine the treatment’s effectiveness in reducing symptoms and improving the quality of life for those with olive pollen allergies. The study will also assess the safety and any side effects of the treatment.

The trial will take place over a period of time, with participants being asked to keep track of their symptoms and any medications they use. This information will be used to evaluate the treatment’s impact on their condition. The goal is to find a balance between the benefits and any potential risks of the treatment, ensuring it is both effective and safe for patients with olive pollen allergies.

The purpose of the study is to see how effective this treatment is in reducing the symptoms of allergic rhinitis and rhinoconjunctivitis over a period of one year. Participants will receive either the PURETHAL treatment or a placebo. The study will involve regular visits to the clinic for injections and assessments. Participants will be asked to keep a daily diary of their symptoms and any changes they notice. The study will also monitor the safety of the treatment and any side effects that may occur.

In addition to the main treatment, the study will use various tests to assess the participants’ allergic reactions. These include skin-prick tests with substances like dog epithelia, cat epithelia, and mugwort pollen extract, as well as nasal sprays and eye drops containing substances like loratadine and azelastine. These tests help to understand how the body reacts to different allergens and to measure the effectiveness of the treatment. The study aims to provide valuable information on managing allergic conditions caused by house dust mites.

The purpose of the study is to determine how well these Ketotifen eye drops work in reducing the symptoms of Seasonal Allergic Conjunctivitis and to ensure they are safe for use. Participants in the study will be randomly assigned to receive either the Ketotifen eye drops, Ketoftil, or a placebo. The study will last for a period of two weeks, during which participants will use the eye drops and report any changes in their symptoms. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results.

Throughout the study, participants will be asked to self-assess their level of eye itching using a simple scale. Other symptoms, such as eye redness, tearing, and eyelid swelling, will be evaluated by the study investigators at various intervals. The overall safety and tolerability of the treatments will also be monitored. This trial aims to provide valuable information on the potential benefits of Ketotifen eye drops for individuals suffering from Seasonal Allergic Conjunctivitis.

The purpose of the study is to see how well the T502 treatment works in reducing allergy symptoms and the need for other allergy medications during the peak birch pollen season. Participants in the study will receive either the T502 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will compare the symptoms and medication use between those receiving the actual treatment and those receiving the placebo.

Participants will be involved in the study for a period that includes the peak birch pollen season. During this time, they will receive regular injections and will be monitored for any changes in their allergy symptoms. The study aims to provide valuable information on the effectiveness of T502 in managing symptoms of birch pollen allergies.

The purpose of this study is to evaluate how effective and safe the PQ Birch treatment is for individuals affected by birch pollen allergies. Participants in the study will receive either the PQ Birch treatment or a placebo, which is a substance with no active medication. The study is designed to be randomised and double-blind, meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will attend several visits where they will receive injections and have their health monitored. The study will last for a period of time that includes the birch pollen season, allowing researchers to observe the treatment’s effects during peak allergy times. The main goal is to see if the treatment can reduce the symptoms of hay fever and improve the quality of life for those affected by birch pollen allergies.